Labcorp, Pillar Biosciences team up for genomic testing

By LabPulse.com staff writers

October 19, 2021 -- Labcorp and Pillar Biosciences have signed an agreement to offer genomic cancer testing based on Pillar's next-generation sequencing (NGS) technology.

Under the deal, Pillar will provide its OncoReveal Essential myeloproliferative neoplasm (MPN) panel. The test simultaneously measures for DNA mutations across multiple genes, according to the vendor.

GeneCentric Therapeutics teams up with Labcorp
GeneCentric Therapeutics has formed a strategic partnership with Labcorp to develop and commercialize RNA-based gene signatures for oncology diagnostics.
Labcorp acquires women's digital health firm Ovia
Labcorp announced it has acquired digital health firm Ovia Health in a move the company said aims to improve patient experience and reduce healthcare...
Labcorp deploys new SARS-CoV-2 sequencing panel
Labcorp will start using Molecular Loop Biosciences' SARS-CoV-2 research sequencing panel to sequence thousands of complete coronavirus genomes each week...
OmniSeq, Labcorp launch new oncology test
OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and...
Labcorp to buy intellectual property from Myriad Genetics
Labcorp plans to buy some of Myriad Genetics' operating assets and intellectual property from its autoimmune business unit, including its Vectra rheumatoid...

Copyright © 2021 LabPulse.com

Last Updated ls 10/19/2021 4:18:08 PM